3 Healthcare Stock Stories Starting a Tuesday Buzz

ACADIA Pharmaceuticals (NASDAQ:ACAD): Closing price $18.43

On Tuesday, ACADIA presented data from its Phase III program with pimavanserin for Parkinsons disease psychosis, which included data from its pivotal -020 Study and the related, open-label safety extension evaluation, at a poster session at the 17th International Congress of Parkinsons Disease and Movement Disorders in Sydney. Data from the open-label safety extension study showed that long-term administration of pimavanserin is primarily safe and well tolerated in PDP patients, and implied that the duration of antipsychotic effect might be maintained for more than the six weeks investigated in the pivotal -020 Study. ACADIA is  a biopharmaceutical firm focused on innovative treatments that meet unmet medical needs in neurological and related central nervous system disorders

Are these stocks a buy or sell? Let us help you decide. ACAD